Announcement on the General Election of the Board of Directors and the Board of Supervisors
Release time:
2021-05-20
证券代码:600668 证券简称:尖峰集团 公告编号:2020-028
浙江尖峰集团股份有限公司
关于董事会、监事会换届选举的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
浙江尖峰集团股份有限公司(以下简称“本公司”)第十届董事会、第九届监事会任期将于2020年11月16日届满,根据《公司法》、《证券法》及《公司章程》的规定,董事会、监事会任期为三年,公司应按照程序进行换届选举工作。现将本次董事会、监事会换届选举情况说明如下:
一、董事会换届选举情况
(1)董事会换届选举的基本情况
本公司第十一届董事会由9名董事组成,其中非独立董事6名、独立董事3名。第十一届董事会董事候选人名单如下(简历附后):
提名蒋晓萌先生、虞建红先生、刘波先生、张国平先生、黄速建先生、黄金龙先生为公司第十一届董事会非独立董事候选人;
提名傅颀女士、沈卫国先生、杨大龙先生为公司第十一届董事会独立董事候选人。
(2)履行的审议程序
2020年10月29日,公司第十届董事会提名委员会以通讯表决的方式召开了关于董事会换届选举的会议,公司现有三名提名委员会成员全部参加了会议,提名委员会对9名候选人的相关资料进行了审核,认为9名董事候选人具备担任上市公司董事的资格,符合《公司章程》规定的任职条件,同意将上述9名候选人提交公司十届17次董事会审议。
2020年10月30日,公司以通讯表决的方式召开了第十届董事会第17次会议,公司现有八名董事全部参加了会议,经审议与表决,董事会以8票同意、0票反对、0票弃权,审议通过了《关于董事会换届选举的议案》。
公司独立董事对上述议案发表了独立意见,认为:本次提名的非独立董事候选人具备法律、行政法规所规定的上市公司董事任职资格,具备履行董事职责所必需的工作经验,符合《公司章程》的规定,提名程序合法、有效;本次提名的独立董事候选人具有独立性和履行独立董事职责所必需的工作经验,符合《关于在上市公司建立独立董事制度的指导意见》、《上市公司治理准则》、《公司章程》的规定,提名程序合法、有效;未发现董事候选人有《公司法》、《公司章程》及《关于在上市公司建立独立董事制度的指导意见》中规定的不得担任公司董事、独立董事的情形,不存在被中国证券监督管理委员会确认为市场禁入者且禁入尚未解除的情形。董事会决议的形成符合《公司法》、《公司章程》等有关规定,没有损害中小股东的利益。
独立董事候选人声明及提名人声明详见公司于上海证券交易所网站(www.sse.com.cn)发布的相关附件。
以上9名董事候选人将提交公司2020年第一次临时股东大会选举,本次股东大会将提供网络投票,不采取累积投票制选举,每位董事候选人以单项提案提出。
二、监事会换届选举情况
(1)监事会换届选举的基本情况
公司第十届监事会由5名监事组成,其中股东大会选举的监事3名、职工代表监事2名。第十届监事会股东大会选举的监事候选人名单如下(简历附后):
提名陈天赐先生、吕瑞美女士、石富先生为公司第十届监事会监事候选人。
(2)履行的审议程序
2020年10月30日,公司以通讯表决的方式召开了第九届董事会第11次会议,公司现有五名监事全部参加了会议,经审议与表决,监事会以5票同意、0票反对、0票弃权,审议通过了《关于监事会换届选举的议案》。
以上3名监事候选人将提交公司2020年第一次临时股东大会选举,本次股东大会将提供网络投票,不采取累积投票制选举,每位监事候选人以单项提案提出。
职工代表监事(2名)将由公司职工民主选举产生。3名股东大会选举的监事与2名职工代表监事将共同组成公司第十届监事会。
三、相关附件
1、独立董事候选人声明
2、独立董事提名人声明
3、独立董事关于董事会换届选举的独立意见
特此公告
浙江尖峰集团股份有限公司
董事会
二〇二〇年十月三十一日
附:董事候选人简历
1、蒋晓萌先生:1964年11月出生,工商管理/工程学硕士,教授级高级工程师,执业药师,享受国务院特殊津贴专家,浙江省有突出贡献中青年专家,1980年12月参加工作,先后任金华市水泥厂车间主任,本公司企管部经理,浙江尖峰通信电缆有限公司总经理,浙江尖峰药业有限公司总经理,本公司副总经理、总经理。现任本公司董事长、党委书记,兼任:天士力控股集团有限公司董事局副主席、天士力医药集团股份有限公司副董事长、南方水泥有限公司董事、浙江金华南方尖峰水泥有限公司董事长、金华市通济国有资产投资有限公司董事、浙江省建材工业协会会长、浙江省商会副会长、浙江省企业家协会副会长、浙江省医药行业协会副会长、金华市企业家协会名誉会长、金华市工商业联合会主席、金华市总商会会长。
2、虞建红先生:1966年10月出生,高级经济师、工程师、EMBA,1987年9月参加工作,先后任金华市水泥厂机修车间副主任,技术科科长,金松水泥厂副厂长、厂长,尖峰集团金华金马水泥有限公司总经理,浙江尖峰水泥有限公司总经理,本公司副总经理,现任本公司董事兼总经理,兼任:浙江省水泥协会副会长,天士力控股集团有限公司董事。
3、刘波先生: 1974年11月出生,本科,讲师,1997年8月参加工作。曾任金华广播电视大学教师、学生处副处长、党委校长办公室主任、副校长,金华市通济国有资产投资有限公司副总经理。现任本公司董事,金华市通济国有资产投资有限公司法定代表人、总经理,金华市国有资产经营有限公司法定代表人、董事兼总经理,金华市资产管理有限公司法定代表人、总经理。
4、张国平先生:1976年6月出生,本科,经济师,1999年3月参加工作,先后任金华市公交总公司总经理助理兼安运处副处长、总经理助理兼办公室副主任、安运处处长,金华市城乡公交有限公司经理助理兼办公室主任,金华市公交集团有限公司科技信息部经理,金华市资产管理有限公司总经理助理、副总经理、法定代表人,现任本公司董事、金华市通济国有资产投资有限公司董事兼副总经理、金华市国有资产运营有限公司董事兼副总经理、金华市资产管理有限公司副总经理。
5、黄速建先生:1955年11月出生,经济学博士、研究员,1988年2月至2016年4月在中国社会科学院工业经济研究所工作,曾任中国社会科学院工业经济研究所副所长。现任本公司董事、中国社会科学院工业经济研究所研究员,中国企业管理研究会会长,兼任内蒙古伊泰煤炭股份有限公司独立董事、卧龙电气驱动集团股份有限公司独立董事、青岛海容商用冷链股份有限公司独立董事,安心财产保险有限责任公司董事。
6、黄金龙先生:1965年2月出生,硕士学位,教授级高级工程师、执业药师。1988年8月参加工作,曾任浙江奥托康制药股份有限公司质检科长、副厂长,浙江奥托康制药集团发展部经理;1998年8月加入本公司历任浙江尖峰药业有限公司产品开发部经理、总经理助理、副总经理、常务副总经理、总经理,本公司副总经理。
7、傅颀女士:1979年6月出生,博士、教授,中国注册会计师非执业会员。2006年3月参加工作,现任浙江财经大学会计学专业教授、硕士生导师,兼任杭州天地数码科技股份有限公司、浙江晶盛机电股份有限公司、浙江花园生物高科股份有限公司、浙江日风电气股份有限公司(非上市)、浙江恒强科技股份有限公司(非上市)独立董事。
8、沈卫国先生:1971年6月出生,博士、研究员。1994年7月参加工作,曾任武汉理工大学助教、讲师、副研究员,美国西北大学、加州大学伯克利分校访问学者。现任武汉理工大学博士生导师、研究员,国家水泥标准化技术委员会专家委员、中国建筑学会建材分会理事、中国硅酸盐学会水泥分会理事、湖北省硅酸盐学会理事。
9、杨大龙先生:1964年1月出生,硕士、研究员,1983年参加工作,曾任江苏省药物研究所药师、主管药师、助理研究员、副研究员,现任江苏省药物研究所研究员、所长助理兼办公室主任,兼任南京工业大学硕士生导师、南京恒通医药开发有限公司总经理。
附:监事侯选人简历
陈天赐先生,1962年11月出生,本科,高级工程师。1985年8月参加工作,先后担任本公司金华市水泥厂设备动力科副科长、金华市水泥厂三分厂技术科科长、公司技术开发部经理、生产管理部经理、企业管理部经理、浙江尖峰水泥有限公司副总经理、公司投资管理部经理、金华尖峰陶瓷有限公司常务副总经理、浙江尖峰投资有限公司副总经理、审计业绩管理部经理、尖峰集团公司总经理助理、云南尖峰水泥有限公司总经理等职务。现任本公司监事会主席。
吕瑞美女士,1971年9月出生,本科,会计师。1993年7月参加工作,曾任福建省金属材料总公司会计,浙江八达股份有限公司会计及主管,金华禾信联合会计师事务所审计员,金华安泰会计师事务所项目经理,浙江中健会计事务所项目经理,现就职于金华市通济国有资产投资有限公司、本公司监事,兼任金华市交通投资集团有限公司监事。
石富先生,1972年11月出生,本科,高级经济师。1995年7月参加工作,先后在浙江省水泥制品厂,本公司企业管理部、总经理办公室工作,现任大冶尖峰水泥有限公司总经理助理、工会主席、党支部副书记;本公司监事。
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05